ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
92 hedge funds and large institutions have $577M invested in Adaptimmune Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
12% more funds holding
Funds holding: 82 → 92 (+10)
0.05% less ownership
Funds ownership: 11.97% → 11.92% (-0.05%)
Holders
92
Holding in Top 10
–
Calls
$2.49M
Puts
$1.96M
Top Buyers
| 1 | +$11.4M | |
| 2 | +$6.97M | |
| 3 | +$5.06M | |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.48M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.23M |
Top Sellers
| 1 | -$8.89M | |
| 2 | -$8.76M | |
| 3 | -$8.62M | |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$5.63M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$4.34M |